about
Mechanisms of drug resistance in colon cancer and its therapeutic strategiesGlycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapyExport of microRNAs: A Bridge between Breast Carcinoma and Their Neighboring CellsROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic StrategiesCancer drug resistance: redox resetting renders a wayDrug Delivery Using Nanoparticles for Cancer Stem-Like Cell TargetingCancer therapy in the necroptosis eraCancer Stem Cell Plasticity Drives Therapeutic ResistanceBladder Cancer Stem-Like Cells: Their Origin and Therapeutic PerspectivesKilling cancer with platycodin D through multiple mechanismsCombined Treatments with Photodynamic Therapy for Non-Melanoma Skin CancerTherapies targeting cancer stem cells: Current trends and future challengesPrecision medicine for cancer with next-generation functional diagnosticsDifferentiation and transdifferentiation potentials of cancer stem cellsCaveolin-1, a stress-related oncotarget, in drug resistanceTargeting Breast Cancer MetastasisIndirubin and Indirubin Derivatives for Counteracting Proliferative DiseasesAutophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and MetastasisMitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer ChemotherapyTargeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer CellsProtecting the normal in order to better kill the cancerEvolutionary determinants of cancerMultidrug resistance and cancer stem cells in neuroblastoma and hepatoblastomaCancer stem cells--important players in tumor therapy resistanceDeciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineTargeting cancer with kinase inhibitorsTumour heterogeneity and the evolution of polyclonal drug resistanceIntegrative analysis of cancer imaging readouts by networksResistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategiesBridging scales in cancer progression: mapping genotype to phenotype using neural networksZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistancePrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesThe emerging molecular machinery and therapeutic targets of metastasisAbl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and MotilityEnzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapyAntivascular and antitumor properties of the tubulin-binding chalcone TUB091Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosisInhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.Cancer's Achilles' Heel: Apoptosis and Necroptosis to the RescueNew trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
P2860
Q26738528-0B72CD16-C255-442E-8D5A-4050BA0C0234Q26739711-85FEB432-1727-4EE3-BA1C-B26D4850C862Q26744487-97B51377-8065-4C04-89B1-4745626A9F67Q26747496-D7744FFD-E2DF-4F8B-90C9-FA05B67ED65DQ26750753-37D87E62-15CA-416C-858C-20FEFF90015EQ26752688-2627A672-D317-4CE4-8908-E72038DBA807Q26766339-97657812-9601-4D51-9390-494BC297DA0DQ26770274-80761C2F-52B5-4641-B3F4-B7BA73CBD439Q26771263-A3DC7315-6BCC-402A-AC51-74C3DE6A6031Q26773408-23FAE310-C882-4B4A-9BA4-224EB29D5D28Q26777814-B87BCC2B-82B2-413A-B10D-4CDABE927006Q26777880-19D6D594-7773-4336-9202-26033A8C7448Q26780232-CDFC7CC3-84BB-4FDE-B158-70CAA150F62CQ26782242-99AAF22F-049D-47BA-926C-2BB0272B66F9Q26782615-EE23690F-C07E-451B-99F6-A042EBFA99E4Q26783925-1DE0945C-58D1-4FAA-9C54-B069BAD0662EQ26784341-446797C0-DAE1-4A90-BC1D-136E5F31B9D3Q26796793-6BCAE7C9-5F59-4068-8858-B4CBE0969633Q26797353-00EA81FB-2CAC-4B38-8B76-ACB0B9677A0BQ26798203-FBCF94D1-1E42-44F7-8432-60A3B107BA5CQ26801291-15B9C1FC-9871-4031-BC4C-B9A5027EB7D8Q26801710-B2B04F63-42FD-4BD4-B584-6301C17FAE09Q26822652-3E9740AB-A920-4E7A-A9EE-95B9248C7255Q26823015-C67C28E7-4E08-40FE-A951-65AAB4840647Q26825186-50E2EEAD-54BA-4088-98CB-05B23AE9780AQ26865765-4955B474-9B9A-48ED-8A4A-6ED81DF6C15DQ26866803-AEE52FAD-486D-4239-B956-8C6379BE65CEQ26999069-170831E4-1BD0-4406-95D5-0F66888185E9Q27004161-BA1E0832-75C5-4C8F-ABF1-595C325F8B5EQ27005804-BA3453C7-D408-4078-8592-6878D5047851Q27015111-9145DE3B-9464-4ED3-A84C-5D8812E9FCE4Q27015224-3DAB0476-59ED-4805-A12D-B9094AD146A8Q27022207-651F3404-BF93-44D7-96B8-0CC29F4D0F26Q27308835-53EB5FF3-1FB7-4957-86EA-8C8874FBAB7BQ27701980-CB1EC1AC-5277-41D0-A81F-E23710BFF136Q27705273-8D56B445-E7D2-4C5A-9549-FFF8889ADC28Q27853047-840626D1-C01B-4C34-A305-4BA63356DEDFQ27853177-408657CD-B638-4E3C-897C-78B5DD7B7D0BQ28066868-B2C58C7E-22C3-4F68-BBD6-CCDD5C57D21FQ28067499-0FEF07B8-85DB-4F9B-BBA8-A7E5CFDEFD1F
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cancer drug resistance: an evolving paradigm
@ast
Cancer drug resistance: an evolving paradigm
@en
type
label
Cancer drug resistance: an evolving paradigm
@ast
Cancer drug resistance: an evolving paradigm
@en
prefLabel
Cancer drug resistance: an evolving paradigm
@ast
Cancer drug resistance: an evolving paradigm
@en
P2093
P3181
P356
P1476
Cancer drug resistance: an evolving paradigm
@en
P2093
Johnston PG
Longley DB
Van Schaeybroeck S
P2888
P304
P3181
P356
10.1038/NRC3599
P407
P577
2013-10-01T00:00:00Z
P6179
1026519625